Live Breaking News & Updates on Marshall woodworth

Stay informed with the latest breaking news from Marshall woodworth on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Marshall woodworth and stay connected to the pulse of your community

NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update

Received First Site Institutional Review Board (IRB) Approval to Proceed With the Phase 1 Trial of DA-1726 in Obesity Phase 1 Trial of DA-1726 Expected to Dose...

Miami , Florida , United-states , Cambridge , Cambridgeshire , United-kingdom , Alexander-prezioso , Marshall-woodworth , Jamesp-tursi , Development-rd-expenses , Neurobo-pharmaceuticals-inc-nasdaq , Fund-the-company-into-fourth-quarter

NeuroBo Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

DA-1726 Phase 1 IND Filing Expected by Year End 2023
Board Strengthened with Recent Appointment of Industry Veteran, James P. Tursi, M.D.
Cash and Cash Equivalents of $25.8 Million, Expected to Fund...

United-states , Texas , Boston , Massachusetts , Marshall-woodworth , Michael-miller , Zeid-kayali , Jamesp-tursi , David-ramirez , Fund-the-company-into-fourth-quarter , Neurobo-pharmaceuticals , Nasdaq

New Speakers of French in Louisiana: Continuing a Legacy

In Lafayette, former immersion students are establishing the institutions necessary to support a new generation of francophones.

France , New-orleans , Louisiana , United-states , Evangeline-elementary-school , Acadiana , Sainte-anne , Midi-pyrées , Sydney , New-south-wales , Australia , Canada

BioNJ Announces Lineup for BioPartnering Conference

/PRNewswire/ -- BioNJ is pleased to host its 13th Annual BioPartnering Conference on Tuesday, April 18, 2023, at The Palace at Somerset Park, Somerset, NJ....

Jersey , Somerset-park , New-jersey , United-states , Rutgers-university , District-of-columbia , Boston , Massachusetts , Trenton , Penn-center , Middlesex-county , Princeton-university

BioNJ Announces Lineup for BioPartnering Conference

BioNJ Announces Lineup for BioPartnering Conference
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Jersey , Somerset-park , New-jersey , United-states , Rutgers-university , District-of-columbia , Boston , Massachusetts , Trenton , Penn-center , Middlesex-county , Princeton-university

Nevakar Injectables Sells Six Development-Stage, Ready-to-Use Injectable Product Candidates to Endo Ventures Limited

BRIDGEWATER, N.J., May 02, 2022 -- Nevakar Injectables Inc. , a wholly owned subsidiary of Nevakar, Inc., is a biopharmaceutical company developing multiple sterile injectable products for use in... | May 2, 2022

Lisam-wilson , Marshall-woodworth , Linkedin , Endo-international , Nevakar-injectables-inc , Endo-ventures , Site-communications-inc , Nevakar-inc , Globenewswire-inc , Ventures-limited , Site-communications , Endo-international-plc-stock-exchange

Nevakar Announces Closing of $12 Million Convertible Note and Extension of Interest-Only Period with Oxford Finance

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

New-york , United-states , New-jersey , Alexandria , Al-iskandariyah , Egypt , Palo-alto , California , Boston , Massachusetts , Virginia , Bridgewater

Nevakar Announces Formation Of Ophthalmic Company, Vyluma

Nevakar Announces Formation Of Ophthalmic Company, Vyluma
News provided by
Share this article
Share this article
BRIDGEWATER, N.J., May 25, 2021 /PRNewswire/ -- Nevakar Inc. ("Nevakar"), a privately held biopharmaceutical company, today announces the establishment of Vyluma Inc., a newly formed company with a focus on the development and commercialization of therapies to treat ophthalmic diseases. At inception Vyluma will operate as a wholly owned subsidiary of Nevakar Inc.
Vyluma will focus on first-in-class and best-in-class ophthalmic pharmaceutical therapies, with an emphasis on refractive errors. Currently, there are no pharmaceutical treatment options approved for refractive errors such as childhood myopia, presbyopia, night vision disturbance, and hyperopia. NVK002 is Vyluma's lead product candidate in late Phase III clinical development with readouts anticipated in the fourth quarter of 2022. If approved, it would be the first pharmaceutical therapy to slow the progression of myopia in children.

China , Houman-hemmati , Raula-trillo-jr , Marshall-woodworth , Vyluma-inc , Nevakar-inc , Navneet-puri , Financial-officer , Chief-commercial-officer , Chief-medical , Chief-medical-officer , Tuyen-ong

Nevakar and Théa Enter into Licensing Agreement for the Commercialization of NVK-002 (Atropine ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Nevakar and Théa Enter into Licensing Agreement for the Commercialization of NVK-002 (Atropine ...
Nevakar, Inc.January 28, 2021 GMT
-- Potential to receive up to $135 million upon the successful attainment of several key regulatory and sales milestones --
BRIDGEWATER, N.J. and CLERMONT-FERRAND, France, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Nevakar Inc. (“Nevakar”), a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, and Laboratoires Théa (“Théa”) announced today that they recently entered into an exclusive licensing agreement for the commercialization of NVK-002 in Europe. NVK-002 is a proprietary, investigational, preservative-free eye drop administered nightly and intended for slowing the progression of myopia in children ages three to 17. It is currently under clinical evaluation in the CHAMP (Childhood Atropine for Myopia Progression) study, a Phase III clinical trial being carried out in the U.S. and Europe.

Taiwan , Clermont-ferrand , Auvergne , France , United-states , Hong-kong , New-jersey , China , South-korea , Republic-of-china , Taiwan-general , Macau